Lupus nephritis (LN) is a form of glomerulonephritis that constitutes one of the most severe
organ manifestations of the autoimmune disease systemic lupus erythematosus (SLE). Most …

The heterogeneity of systemic lupus erythematosus (SLE), long recognised by clinicians, is
now challenging the entire lupus community, from geneticists to clinical investigators …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Background Voclosporin, a novel calcineurin inhibitor approved for the treatment of adults
with lupus nephritis, improved complete renal response rates in patients with lupus nephritis …

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

Objective To update the 2012 EULAR/ERA–EDTA recommendations for the management of
lupus nephritis (LN). Methods Following the EULAR standardised operating procedures, a …

Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the
epidemiology of LN and its clinical presentation have been changing. However, even …

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis
(BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients …

The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

Objectives Treat-to-target recommendations have identified 'remission'as a target in
systemic lupus erythematosus (SLE), but recognise that there is no universally accepted …